Trial Profile
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose, Parallel-Group, Relative Bioavailability Study to Evaluate the Pharmacokinetics of ZYN002 (CBD) Following Application to the Skin of the Upper Arms/Shoulders Compared to Upper Arms/Shoulders and Upper Thighs
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Epilepsy; Fragile X syndrome; Osteoarthritis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Zynerba Pharmaceuticals
- 27 Apr 2019 Status changed from recruiting to completed.
- 27 Feb 2018 Status changed from not yet recruiting to recruiting.
- 06 Feb 2018 New trial record